In This Section

Abstracts

Abstract Submission DeadlineThursday, November 19, 2020

Special abstract solicitation: COVID-19 and Cancer

The Program Committee welcomes abstracts on all aspects of COVID-19 and Cancer for consideration for oral and poster presentation at the AACR Annual Meeting 2021. Submissions in the following subcategories will be considered:

  • Intersection of the Biology of SARS-CoV-2 and Cancer
  • Diagnostics for COVID-19 Testing: Design, Development, and Validation
  • Cancer Drug Repurposing to Treat COVID-19
  • COVID-19 Vaccine Development
  • Effects of Cancer Immunotherapies on Patients with COVID-19 (with or without Cancer)
  • Clinical Trials (all COVID-19 clinical trial abstracts should be submitted for the January 11 clinical trials abstract deadline)
  • Continuity of Cancer Care
  • Effects of COVID-19 on Cancer Survivorship
  • Risk Factors and Comorbidities Resulting in Adverse Outcomes for Cancer Patients with COVID-19
  • Cancer Prevention and Early Detection during the COVID-19 Pandemic
  • Epidemiology and Registries of COVID-19 and Cancer (including Biorepositories)
  • Health Inequalities and Disparities during the COVID-19 Pandemic
  • Science and Public Policy

Further details on COVID-19 and Cancer subcategories are available on page 23 of the Abstract Categories list in the Call for Abstracts.

GUIDELINES FOR PREPARATION AND SUBMISSION OF ABSTRACTS

AACR Abstract Submission System. Authors must submit abstracts for presentation at the Annual Meeting 2021 using the AACR Abstract Submission System. You can create, modify, and submit abstracts until the November 19, 2020, abstract deadline.

To log into the abstract submission system, you must have a myAACR account. If you do not have a myAACR account, you will be given the opportunity to create one during the login process.

Note for 2021: Submit your abstract detailing how you use AACR Project GENIE data by the November 19, 2020, deadline for an opportunity to be featured in a special session during the Annual Meeting 2021. Simply include GENIE as a keyword during the submission process.

Abstract Submission Customer Service: 217-398-1792 or [email protected].

Guidelines for Preparation and Submission of Abstracts Submit Abstract

Financial Relationships of Coauthors. Per ACCME regulations, the AACR must collect information on the financial relationships of all meeting presenters and abstract authors. You will be asked to disclose your financial relationships and the financial relationships of each of your coauthors. For more information on financial relationships.

Sponsor Permission and Information. Each abstract must be sponsored by an AACR member. You must secure the permission of the sponsor before submitting the abstract. For details, see the “Abstract Sponsorship Regulations” section.

Abstract Category, Subcategory, and Subclassification. You must select a category, subcategory, and subclassification for your abstract.

Abstract Category, Subcategory, and Subclassifications List

Submission Fee. Each abstract submitted must be accompanied by a $65 abstract submission fee. The submission fee can be paid by credit card or check. The fee is nonrefundable regardless of the final disposition of the abstract.

Abstract Deadline. The deadline for abstract submissions is 11:59 p.m. U.S. ET, Thursday, November 19, 2020. Abstracts submitted after the deadline will not be considered by the Program Committee. No significant changes may be made to abstracts after the November 19, 2020, deadline.

Note: Submitting an abstract for presentation at the AACR Annual Meeting 2021 does not constitute registration for the meeting. Abstract presenters must register to attend the meeting.

Late-Breaking Abstract Deadline

The deadline for late-breaking abstracts is 11:59 p.m. U.S. ET, Monday, January 11, 2021. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline will be considered for presentation at the Annual Meeting. Only those abstracts that are deemed to be of high scientific priority will be accepted.

Abstract submission fees and sponsorship regulations also apply to late-breaking abstracts.

Clinical Trials Abstract Deadline

All abstracts describing clinical trials (including placeholder abstracts) should be submitted as late-breaking abstracts. The deadline for clinical trials abstracts is 11:59 p.m. U.S. ET, Monday, January 11, 2021. Final data for placeholder abstracts are due Thursday, February 4, 2021. Abstract submission fees and sponsorship regulations also apply to clinical trials abstracts. Learn more.

Publication Opportunity. For consideration of simultaneous publication in an AACR journal, please contact the AACR Publishing Division at [email protected].

Presentation of Proffered Papers at the AACR Annual Meeting

Every proffered abstract that has been accepted for publication in the online Proceedings must have a corresponding presentation at the meeting. Specifically, the author listed as the presenter for an accepted proffered paper must attend the corresponding session to discuss in detail the research outlined in the published abstract, according to the specific guidelines of the session. Presentation formats for 2021 include ePosters with enhanced engagement and networking opportunities and short talks in minisymposia. If, due to unforeseen circumstances, the designated presenter is unavailable to attend the session to present the paper, he or she must contact the AACR Program Development Department to designate a coauthor to serve as the presenter. If no abstract authors are available to present the data, the presenter must withdraw the abstract immediately by contacting the AACR Program Development Department at 215-440-9300 or [email protected]. Failure to comply with these regulations pertaining to abstract presentation may result in actions including, but not limited to:

Deadline for Withdrawal of Abstracts

Requests to withdraw regular abstracts will be accepted through Monday, February 22, 2021. Requests to withdraw late-breaking or clinical trials abstracts will be accepted through Tuesday, March 9, 2021. Withdrawal requests must be sent by email to [email protected]. Withdrawal requests must include the Abstract Control Number and title as well as an explanation of the reason for withdrawal.